MYOK MyoKardia Inc.

-0.15  -0%
Previous Close 50.22
Open 50.26
Price To Book 3.77
Market Cap 2,306,750,135
Shares 46,070,504
Volume 34,603
Short Ratio
Av. Daily Volume 411,136

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
Mavacamten (MYK-461) - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 interim positive data released March 4, 2019. Data to be presented at ESC August 31-September 4, 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data due 4Q 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2a top-line data due 2H 2019.
Heart failure

Latest News

  1. MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
  2. Were Hedge Funds Right About Flocking Into MyoKardia, Inc. (MYOK) ?
  3. The MyoKardia (NASDAQ:MYOK) Share Price Is Up 218% And Shareholders Are Boasting About It
  4. MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
  5. Edited Transcript of MYOK earnings conference call or presentation 9-May-19 8:30pm GMT
  6. MyoKardia, Inc. (MYOK) Q1 2019 Earnings Call Transcript
  7. MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates
  8. MyoKardia: 1Q Earnings Snapshot
  9. MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
  10. MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
  11. MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
  12. Here’s What Hedge Funds Think About MyoKardia, Inc. (MYOK)
  13. Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
  14. Can We See Significant Institutional Ownership On The MyoKardia, Inc. (NASDAQ:MYOK) Share Register?
  15. Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance — What Drives Growth in Today's Competitive Landscape
  16. MyoKardia Announces Pricing of Public Offering of Common Stock
  17. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  18. MyoKardia Announces Proposed Public Offering of Common Stock
  19. MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference